Wave Life Sciences (WVE) Current Deferred Revenue (2014 - 2026)

Wave Life Sciences' Current Deferred Revenue history runs 12 years deep, the most recent figure standing at $9.4 million for Q1 2026.

• Quarterly Current Deferred Revenue fell 83.61% year-over-year to $9.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (down 83.61% YoY) and the FY2025 annual result came in at $44.4 million, down 32.64% from the prior year.
• Current Deferred Revenue was $9.4 million for Q1 2026 at Wave Life Sciences, down from $44.4 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $150.1 million in Q4 2023 and bottomed at $9.4 million in Q1 2026.
• A 5-year average of $74.3 million and a median of $57.3 million in 2025 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue soared 375.5% — and 2026, when it sank 83.61%.
• Wave Life Sciences' Current Deferred Revenue stood at $31.6 million in 2022, then surged by 375.5% to $150.1 million in 2023, then sank by 56.04% to $66.0 million in 2024, then plunged by 32.64% to $44.4 million in 2025, then sank by 78.86% to $9.4 million in 2026.
• Business Quant data shows WVE's Current Deferred Revenue at $9.4 million in Q1 2026, $44.4 million in Q4 2025, and $46.5 million in Q3 2025.